Order before 3pm, dispatched same day
Order before 3pm, dispatched same day Research Use Only
Pay by Card / Apple Pay
99% Purity Money Back Guarantee Retatrutide Now Available

MK-677 vs GH Peptides: Hormone Research Comparison

Back to library
peptide

MK-677 vs GH Peptides: Hormone Research Comparison

20 min read
Hormone Research
GH Secretagogues
Research Comparison
Last Updated: May 2026

MK-677 (Ibutamoren) and GH secretagogue peptides — including GHRP-2, Ipamorelin, and CJC-1295+DAC — share a common mechanistic upstream target but differ substantially in route of administration, receptor selectivity, half-life, and breadth of published human trial data. This article provides a structured research comparison of MK-677 versus injectable GH secretagogue peptides, specifically in the context of GH-axis and anabolic hormone axis research. MK-677 is not a peptide — it is a non-peptide oral ghrelin mimetic — and it is not carried by Pure Grade Labs. The compounds PGL supplies are injectable ghrelin mimetics (GHRP-2, Ipamorelin) and a GHRH analogue (CJC-1295+DAC), which are frequently searched alongside MK-677 by researchers evaluating GH-axis secretagogue options. All content is framed from a research and mechanistic perspective. These compounds are supplied strictly as research chemicals — not for human consumption.

Key Takeaways

  • MK-677 is a non-peptide oral ghrelin mimetic (GHS-R1a agonist) — it is not a peptide, and should not be classified alongside injectable peptide secretagogues despite acting on the same receptor class.
  • GHRP-2 and Ipamorelin are injectable ghrelin mimetics that act on the same GHS-R1a receptor as MK-677, but with significantly shorter half-lives and different selectivity profiles — providing tighter experimental control in GH pulsatility research.
  • CJC-1295+DAC acts on a different receptor entirely (GHRHR, not GHS-R1a), making it mechanistically complementary rather than comparable to MK-677; in published research, GHRH analogues and ghrelin mimetics are studied in combination for synergistic GH release.
  • GH secretagogues are studied in the context of the GH/IGF-1 axis — and published research has explored the relationship between GH-axis activity and broader anabolic hormone signalling, including IGF-1 elevation that occurs downstream of GH stimulation.
  • In the UK, GHRP-2, Ipamorelin, and CJC-1295+DAC are legally available as research chemicals; MK-677 (Ibutamoren) is not a controlled substance under the MDA 1971 but sits in a more ambiguous legal category as it progressed further in clinical development as a candidate drug.
~60–70%
MK-677 oral bioavailability in published pharmacokinetic studies (Chapman et al., 1996)
3–5×
Peak GH pulse amplitude increase above baseline with GHRP-2 in dose-response studies (Ghigo et al., 1994)
~19 days
CJC-1295+DAC half-life via albumin-binding DAC technology (Jette et al., 2005)
+40–72%
IGF-1 elevation reported in published GH secretagogue clinical research (Nass et al., 2008; Jette et al., 2005)

GH Optimization Research Stack — GHRP-2 + CJC-1295+DAC

Research-grade ghrelin mimetic and GHRH analogue combination for GH-axis laboratory research. HPLC-verified, batch COA included.

View GH Research Stack →

What Is MK-677 (Ibutamoren)? Mechanism Overview

MK-677, also known by its INN (International Non-proprietary Name) Ibutamoren, is a non-peptide, orally active growth hormone secretagogue that acts as a selective agonist of the growth hormone secretagogue receptor type 1a (GHS-R1a) — the same receptor that binds endogenous ghrelin. It was developed by Merck & Co. in the 1990s as an investigational candidate for GH deficiency and muscle wasting conditions, entering Phase I and Phase II clinical trials before development was discontinued for commercial reasons rather than safety findings.

The defining characteristic of MK-677 relative to peptide GH secretagogues is its route of administration: MK-677 is orally bioavailable at approximately 60–70% (Chapman et al., 1996) — a remarkable figure for a compound targeting a receptor that is also engaged by endogenous hormones requiring parenteral administration. This oral bioavailability is achieved through a carefully designed non-peptide scaffolding structure that resists first-pass hepatic metabolism. MK-677 has a plasma half-life of approximately 4–6 hours following oral dosing, enabling once-daily administration in the clinical trial setting.

Upon GHS-R1a activation, MK-677 stimulates GH release from the anterior pituitary through two complementary pathways: direct pituitary stimulation of GH secretion and amplification of hypothalamic GHRH release. This dual mechanism — shared with peptide ghrelin mimetics — explains why MK-677 produces supraphysiological GH pulses in research subjects. In published Phase II trials (Nass et al., 2008; Chapman et al., 1996), MK-677 administration in healthy adults and older populations produced statistically significant, dose-dependent GH and IGF-1 elevations sustained over the study period — up to 12 months in the Nass et al. trial.

It is important to note for research classification purposes: MK-677 is emphatically not a peptide. It is a small-molecule GHS-R1a agonist derived from a spiroindoline scaffold. It is searched alongside peptides in the research community because it targets the same receptor class as GHRP-2 and Ipamorelin, but its pharmacokinetics, route of administration, and structural chemistry are entirely distinct.

What Are GH Secretagogue Peptides? GHRP-2 and Ipamorelin

GH secretagogue peptides are synthetic peptides that stimulate GH release from the anterior pituitary — either by acting on GHS-R1a (ghrelin receptor agonists: GHRP-class) or by acting on the GHRH receptor (GHRH analogues: CJC-1295 class). The two receptor pathways are mechanistically distinct but synergistic in combined research protocols.

GHRP-2: The Reference Ghrelin Mimetic Peptide

GHRP-2 (Growth Hormone Releasing Peptide-2) is a synthetic hexapeptide (six amino acids: His-D-Trp-Ala-Trp-D-Phe-Lys-NH₂) that acts as a potent GHS-R1a agonist. Unlike MK-677, GHRP-2 is a true peptide — and like all peptide GH secretagogues, it requires parenteral administration (typically subcutaneous or intravenous in laboratory settings) due to rapid enzymatic degradation in the GI tract. GHRP-2 has a plasma half-life of approximately 15–60 minutes, generating discrete, acute GH pulses that closely mimic the physiological pulsatility of endogenous GH release.

Published research demonstrates that GHRP-2 at 1 μg/kg IV produces GH pulse amplitudes 3–5× above baseline in healthy adults (Ghigo et al., 1994), with additional documentation of transient cortisol and prolactin co-stimulation — a consequence of GHS-R1a expression in the HPA axis beyond the pituitary. GHRP-2 has become a reference standard compound for GH stimulation testing in the clinical endocrinology research context, with an extensive published evidence base spanning the 1990s through to the 2020s.

Ipamorelin: Selective GHS-R1a Agonism

Ipamorelin is a pentapeptide GHS-R1a agonist developed specifically to address the cortisol and prolactin co-stimulation observed with GHRP-2. Published research by Raun et al. (1998) characterised Ipamorelin as producing robust GH release with markedly reduced cortisol and prolactin stimulation compared to GHRP-2 and GHRP-6 — a selective profile that makes it valuable in research contexts where hormonal confounds must be minimised. Like GHRP-2, Ipamorelin requires parenteral administration and has a short plasma half-life, generating pulsatile GH release patterns.

MK-677 vs GHRP-2: Mechanistic Comparison

MK-677 and GHRP-2 share a common upstream target — GHS-R1a — but diverge substantially in structure, pharmacokinetics, and research applicability. The comparison is of direct relevance to researchers evaluating which compound is more appropriate for a given study design.

Receptor target: Both MK-677 and GHRP-2 act as agonists at GHS-R1a. The receptor binding kinetics differ — MK-677’s non-peptide scaffold allows sustained receptor engagement; GHRP-2 produces acute binding with rapid dissociation consistent with its short plasma half-life.

Route of administration: MK-677 is orally bioavailable (~60–70%). GHRP-2 is a peptide requiring subcutaneous or intravenous administration in laboratory settings — oral administration of peptides results in degradation before systemic absorption.

Half-life and GH release pattern: MK-677’s 4–6 hour half-life following oral dosing results in a prolonged, sustained GH elevation — a tonic rather than pulsatile pattern. GHRP-2’s 15–60 minute half-life generates discrete GH pulses that more closely approximate endogenous physiological GH pulsatility. For research examining GH pulse frequency and amplitude versus sustained GH elevation, this distinction is critical to study design.

Cortisol and prolactin co-stimulation: Both MK-677 and GHRP-2 stimulate GHS-R1a outside the pituitary, including in HPA axis tissues. Published MK-677 trial data (Chapman et al., 1996; Nass et al., 2008) documents cortisol elevations at higher doses but notes these did not result in clinically significant hypercortisolaemia in the trial populations studied. GHRP-2 produces more pronounced acute cortisol and prolactin responses per the published comparative literature.

Depth of published human trial data: MK-677 has substantially more published human clinical trial data than any individual peptide GH secretagogue — including Phase II randomised controlled trials with 12-month follow-up periods, elderly populations, and GH-deficient cohorts. GHRP-2’s human data is extensive but concentrated in shorter-term GH stimulation testing contexts. This depth of MK-677 human trial data is a meaningful distinguishing factor for research literature review purposes.

CJC-1295+DAC: The GHRH Analogue Difference

CJC-1295+DAC (CJC-1295 with Drug Affinity Complex) is fundamentally different from both MK-677 and the GHRP-class peptides. Where MK-677, GHRP-2, and Ipamorelin all act on GHS-R1a, CJC-1295+DAC acts on the GHRH receptor (GHRHR) — a distinct receptor that responds to endogenous Growth Hormone Releasing Hormone (GHRH), the primary hypothalamic regulator of GH secretion.

The DAC (Drug Affinity Complex) technology attached to CJC-1295 enables covalent binding to serum albumin via a reactive lysine residue, dramatically extending the compound’s half-life from minutes (native GHRH) to approximately 19 days in published pharmacokinetic studies (Jette et al., 2005). This extended half-life means CJC-1295+DAC produces sustained elevation of basal GH secretion — effectively raising the GH secretory baseline — rather than generating discrete GH pulses.

In research contexts, CJC-1295+DAC and ghrelin mimetics (GHRP-2, Ipamorelin) are often studied in combination because their mechanistic complementarity produces synergistic GH release. The GHRH receptor pathway and GHS-R1a pathway converge at the somatotroph level — simultaneous activation of both produces greater GH release than either pathway alone. This is the mechanistic basis for the GH Optimization Research Stack combining GHRP-2 with CJC-1295+DAC.

MK-677 has no direct mechanistic equivalent to CJC-1295+DAC’s GHRH pathway activity. In comparative research design terms, a researcher could evaluate MK-677 against GHRP-2 or Ipamorelin for GHS-R1a agonism effects, but comparing MK-677 to CJC-1295+DAC would be comparing two mechanistically orthogonal interventions — both upstream of GH release, but via entirely different receptor pathways.

GH Secretagogues and Anabolic Hormone Axis Research

A significant proportion of researchers searching terms like “testosterone peptides” are investigating the relationship between GH-axis signalling and the broader anabolic hormone axis — particularly the IGF-1 pathway and its downstream interactions with androgen biology. Understanding how GH secretagogues fit into this research landscape requires clarity on what the published literature actually documents.

GH and IGF-1: GH secretagogue administration — whether MK-677, GHRP-2, or CJC-1295+DAC — stimulates pulsatile or sustained GH release, which in turn drives hepatic IGF-1 production. IGF-1 is the primary mediator of GH’s anabolic effects at the tissue level: protein synthesis, nitrogen retention, and cellular proliferation in skeletal muscle and connective tissue. The GH/IGF-1 axis is therefore the mechanistic link between GH secretagogue activity and the anabolic signalling that researchers studying “testosterone peptides” are often interested in exploring.

Published MK-677 trial data (Nass et al., 2008) in healthy older adults documented IGF-1 elevations of approximately 40–72% above baseline at doses of 10–25mg daily, sustained over 12 months. Published CJC-1295+DAC research (Jette et al., 2005) demonstrated dose-dependent IGF-1 increases following a single administration — consistent with the compound’s sustained half-life. GHRP-2 clinical research documents acute IGF-1 elevations correlated with GH pulse magnitude.

GH secretagogues and testosterone: It is important to state clearly what published research does and does not document. GH secretagogues — including MK-677, GHRP-2, Ipamorelin, and CJC-1295+DAC — are studied in the context of GH-axis stimulation and IGF-1 elevation. The published literature does not establish that these compounds directly modulate testosterone production via the hypothalamic-pituitary-gonadal (HPG) axis. Researchers studying the broader anabolic hormone axis should treat GH secretagogues and testosterone/androgen biology as parallel but mechanistically distinct research areas. Claims that GH secretagogues raise testosterone are not supported by the primary published research literature — and should not be framed that way in research design or content contexts.

What is established in the literature is the interaction between the GH/IGF-1 axis and androgen receptor sensitivity at the cellular level — an area of ongoing basic research interest. IGF-1 and androgens share downstream signalling pathways (PI3K/Akt, mTOR), and researchers studying anabolic hormone biology often examine both axes. This is the legitimate research intersection that connects GH secretagogue studies to the broader “anabolic hormone research” space — and where MK-677 and GH secretagogue peptides are contextually relevant.

Safety Profile Comparison: What Published Research Reports

The safety profiles of MK-677 and GH secretagogue peptides have been characterised across multiple published trials. The comparison is relevant to researchers selecting compounds for specific study designs.

MK-677 safety data: The most extensive human safety dataset for any GH secretagogue comes from MK-677 trials. The Phase II 12-month trial by Nass et al. (2008) — conducted in 65 healthy older adults — documented the following primary adverse events: peripheral oedema (related to GH-driven fluid retention), muscle pain, and increased appetite (consistent with GHS-R1a orexigenic activity). Fasting glucose and insulin levels increased over the study period, consistent with GH-driven insulin resistance — a known consequence of sustained GH elevation. No serious cardiovascular or hepatic adverse events were reported. A Phase II trial in patients with hip fractures (Adunsky et al., 2011) similarly documented water retention and musculoskeletal adverse events without serious safety signals.

GHRP-2 and Ipamorelin safety data: Published GHRP-2 safety data documents transient cortisol and prolactin elevation, appetite stimulation, and mild injection-site reactions. No serious adverse events have been reported in published GHRP-2 trials. Ipamorelin‘s more selective receptor profile eliminates the cortisol and prolactin co-stimulation documented with GHRP-2, making it favoured in research contexts where HPA axis confounds are undesirable. The short half-life of both peptide ghrelin mimetics means all adverse events are time-limited and resolve with the pharmacokinetic window.

CJC-1295+DAC safety data: The Jette et al. (2005) Phase I/II study documented CJC-1295+DAC as well-tolerated across the dose range studied, with injection-site reactions as the primary adverse event. The GHRH receptor pathway does not stimulate cortisol or prolactin in the way GHS-R1a does, so CJC-1295+DAC does not share the HPA axis off-target activity of GHRP-2 or MK-677. The extended half-life means any adverse event related to CJC-1295+DAC would be of longer duration than those associated with short-half-life peptides — a relevant consideration for research protocol design.

UK Research Chemical Status: MK-677 vs Peptides

UK legal classification is a relevant consideration for researchers evaluating which GH secretagogue compounds to work with.

MK-677 (Ibutamoren) in the UK: MK-677 is not listed as a controlled substance under the Misuse of Drugs Act 1971. It is not a prescription-only medicine under the Human Medicines Regulations 2012 (HMR 2012) when sold as a research chemical rather than as a medicinal product. However, as a compound that progressed through formal pharmaceutical clinical trials as an investigational new drug, it occupies a more complex regulatory space than many research chemicals. UK researchers should verify current MHRA guidance regarding compounds that were investigated as candidate medicines. The compound is widely available in the UK research chemical market, but the regulatory clarity for peptide-class research chemicals like GHRP-2 is generally considered more straightforward.

GHRP-2, Ipamorelin, CJC-1295+DAC in the UK: These peptides are not listed under the Misuse of Drugs Act 1971. They are not prescription-only medicines under HMR 2012 when sold as research chemicals with appropriate compliance language. They are not psychoactive substances within the scope of the Psychoactive Substances Act 2016 when sold for laboratory research. Pure Grade Labs supplies GHRP-2, Ipamorelin, and CJC-1295+DAC as research chemicals for in vitro laboratory research — strictly not for human consumption — with batch-specific HPLC certificates of analysis and full compliance documentation.

MK-677 vs GH Secretagogue Peptides: Research Comparison Table

Characteristic MK-677 (Ibutamoren) GHRP-2 Ipamorelin CJC-1295+DAC
Compound Type Non-peptide small molecule Synthetic hexapeptide Synthetic pentapeptide Modified GHRH analogue (29AA + DAC)
Receptor Target GHS-R1a (ghrelin receptor) GHS-R1a (ghrelin receptor) GHS-R1a (ghrelin receptor) GHRHR (GHRH receptor) — different receptor class
Administration Route Oral (~60–70% bioavailability) Parenteral (SC/IV in lab settings) Parenteral (SC/IV in lab settings) Parenteral (SC in lab settings)
Half-Life ~4–6 hours (oral) ~15–60 minutes ~2 hours ~19 days (albumin-binding DAC)
GH Release Pattern Sustained / tonic elevation Acute pulsatile GH spikes Acute pulsatile GH spikes Sustained basal GH elevation
Cortisol Co-stimulation Dose-dependent (documented in trials) Yes — significant, transient Minimal — selective profile (Raun et al., 1998) Not via this receptor pathway
Prolactin Co-stimulation Minor (dose-dependent in some trials) Yes — documented, transient Minimal — key selectivity advantage Not via this receptor pathway
Human Trial Data Depth Extensive — Phase II RCTs up to 12 months Extensive — GH stimulation reference standard Moderate — key selectivity characterisation (Raun et al.) Phase I/II data (Jette et al., 2005)
UK Legal Status Not MDA 1971 controlled; more complex regulatory history as IND Research chemical — not controlled Research chemical — not controlled Research chemical — not controlled
Available from Pure Grade Labs No — not in PGL catalogue Yes — GHRP-2 10mg Yes — Ipamorelin 10mg Yes — CJC-1295+DAC 10mg

Research-Grade GH Secretagogue Peptides — UK Stock

GHRP-2, Ipamorelin, and CJC-1295+DAC available for in vitro laboratory research. HPLC-verified purity, batch-specific COA, fast UK dispatch.

View GH Research Stack →

A research team designing a GH pulsatility study in an ageing rodent model faced a key compound selection question. MK-677 offered oral administration and a well-characterised 12-month human safety dataset — but its 4–6 hour half-life would produce sustained tonic GH elevation rather than the discrete pulses the team needed to study. GHRP-2 matched the pulsatile GH pattern required for the protocol, but the team’s primary endpoint was GH pulse amplitude — meaning the cortisol co-stimulation documented in the GHRP-2 literature would need to be measured and controlled for as a co-variate. Ipamorelin’s selective profile eliminated the cortisol confound but produced smaller GH pulses than GHRP-2 at equivalent doses. After reviewing the Raun et al. (1998) selectivity data alongside the Ghigo et al. (1994) GHRP-2 amplitude data, the team selected Ipamorelin at a higher relative concentration to achieve comparable GH pulse amplitude while avoiding the HPA axis confound — a decision made entirely on the basis of published comparative mechanism data.

Frequently Asked Questions

Is MK-677 a peptide?

No. MK-677 (Ibutamoren) is not a peptide. It is a non-peptide, small-molecule GHS-R1a agonist derived from a spiroindoline chemical scaffold. It is orally bioavailable precisely because it is not a peptide — peptides are degraded by GI proteases before systemic absorption. MK-677 is classified as a synthetic ghrelin mimetic because it engages the ghrelin receptor (GHS-R1a), but its structure, pharmacokinetics, and administration route are entirely different from peptide GH secretagogues such as GHRP-2 or Ipamorelin. The frequent grouping of MK-677 with “testosterone peptides” in research searches reflects shared receptor pharmacology and research interest, not structural classification.

How does MK-677 compare to GHRP-2 mechanistically?

Both MK-677 and GHRP-2 act as agonists at GHS-R1a — the endogenous ghrelin receptor. The key mechanistic differences are: (1) MK-677 is orally bioavailable; GHRP-2 requires parenteral administration. (2) MK-677’s 4–6 hour half-life produces sustained GH elevation; GHRP-2’s 15–60 minute half-life generates discrete, pulsatile GH release. (3) Both compounds produce cortisol co-stimulation via HPA axis GHS-R1a expression, but the temporal profiles differ given their pharmacokinetic differences. (4) MK-677 has substantially more published long-term human trial data, including 12-month RCTs. Research design implications flow directly from these mechanistic distinctions: GHRP-2 is more appropriate for pulsatility studies; MK-677 for sustained elevation or oral bioavailability-dependent research contexts.

What is the relationship between GH secretagogues and testosterone in research?

GH secretagogues — including MK-677, GHRP-2, Ipamorelin, and CJC-1295+DAC — are studied primarily in the context of GH-axis stimulation and IGF-1 elevation. The published research literature does not establish that these compounds directly modulate testosterone production via the HPG (hypothalamic-pituitary-gonadal) axis. The research interest connecting GH secretagogues to “testosterone research” typically relates to: (1) the downstream anabolic signalling shared between the IGF-1 pathway and androgen signalling (PI3K/Akt, mTOR); and (2) the broader anabolic hormone axis research context in which GH, IGF-1, and testosterone are all studied as mediators of anabolic signalling in skeletal muscle. Researchers should not frame GH secretagogues as testosterone-modulating compounds — the mechanistic evidence does not support this.

Which GH secretagogues have the most published human trial data?

MK-677 (Ibutamoren) has the largest body of published human clinical trial data of any GH secretagogue compound, including Phase II randomised controlled trials with up to 12-month follow-up, elderly populations, GH-deficient patients, and hip fracture rehabilitation contexts. GHRP-2 has extensive published human data focused on GH stimulation testing and dose-response characterisation (Ghigo et al., 1994, 1996; Arvat et al., 1997, 1998), making it a well-characterised reference standard for GHS-R1a pharmacology. CJC-1295+DAC has Phase I/II human data (Jette et al., 2005). Ipamorelin’s primary published characterisation is in the Raun et al. (1998) selectivity paper; subsequent human trial data is available but less extensive than MK-677 or GHRP-2.

Is MK-677 legal in the UK?

MK-677 (Ibutamoren) is not listed as a controlled substance under the UK Misuse of Drugs Act 1971 and is not classified as a prescription-only medicine under HMR 2012 when sold as a research chemical. It is widely available in the UK research chemical market. However, MK-677 occupies a more complex regulatory position than many research chemicals because it progressed through formal pharmaceutical development as an Investigational New Drug (IND) — meaning MHRA may consider it differently from compounds with no drug development history. Researchers in the UK should verify current MHRA guidance. Note: Pure Grade Labs does not stock MK-677.

Are GHRP-2 and Ipamorelin legal as research chemicals in the UK?

Yes. GHRP-2 and Ipamorelin are not listed under the Misuse of Drugs Act 1971, are not prescription-only medicines under HMR 2012 when correctly sold as research chemicals, and do not fall within the scope of the Psychoactive Substances Act 2016 when sold for in vitro laboratory research purposes. Similarly, CJC-1295+DAC is legally available in the UK as a research chemical. Pure Grade Labs supplies all three compounds with full compliance documentation, batch-specific HPLC COAs, and mandatory research-use-only labelling. Not for human consumption.

GH Secretagogue Peptides — Research Grade, UK Stocked

GHRP-2, Ipamorelin, CJC-1295+DAC and the full GH secretagogue research range. 99%+ HPLC purity, batch COA, fast UK dispatch. Not for human consumption.

Browse Research Catalogue →

Summary

MK-677 (Ibutamoren) and GH secretagogue peptides — GHRP-2, Ipamorelin, and CJC-1295+DAC — are all studied in GH-axis and anabolic hormone axis research contexts, but represent mechanistically, pharmacokinetically, and structurally distinct research tools. MK-677’s defining advantages in research contexts are oral bioavailability and a long half-life enabling sustained GH elevation, alongside the deepest human trial database of any GH secretagogue. Its limitations include tonic rather than pulsatile GH release, and dose-dependent metabolic adverse events (insulin resistance, fluid retention) documented in 12-month trial data.

Injectable GH secretagogue peptides offer different research utilities: GHRP-2 generates acute, physiologically-patterned GH pulses with a well-characterised reference dose for stimulation testing; Ipamorelin offers selective GH release without HPA axis co-stimulation, enabling cleaner GH-endpoint studies; CJC-1295+DAC provides sustained basal GH elevation via the GHRH receptor pathway, synergistic with ghrelin mimetics in the GH Optimization Research Stack. Compound selection in this research space should be driven by the specific mechanistic endpoint, required GH release pattern, and acceptable confound profile — not by oral versus injectable preference alone.

For researchers exploring GH-axis activity in the context of anabolic hormone axis biology, the GH/IGF-1 pathway is the documented mechanistic connection — not direct testosterone modulation. GH secretagogues are not testosterone-modulating compounds, and their research value in anabolic hormone biology lies in their documented effects on GH pulse dynamics and downstream IGF-1 elevation. Pure Grade Labs supplies research-grade GHRP-2, Ipamorelin, and CJC-1295+DAC for in vitro laboratory research in the UK. MK-677 is not carried in the PGL catalogue.

References

  1. Chapman IM, et al. (1996). Stimulation of the growth hormone (GH)-insulin-like growth factor I axis by daily oral administration of a GH secretogogue (MK-677) in healthy elderly subjects. Journal of Clinical Endocrinology & Metabolism, 81(12), 4249–4257. DOI: 10.1210/jcem.81.12.8954023
  2. Nass R, et al. (2008). Effects of an oral ghrelin mimetic on body composition and clinical outcomes in healthy older adults: a randomized trial. Annals of Internal Medicine, 149(9), 601–611. DOI: 10.7326/0003-4819-149-9-200811040-00003
  3. Adunsky A, et al. (2011). MK-0677 (ibutamoren mesylate) for the treatment of patients recovering from hip fracture: a multicenter, randomized, placebo-controlled phase IIb study. Archives of Gerontology and Geriatrics, 53(2), 183–189. DOI: 10.1016/j.archger.2010.10.004
  4. Ghigo E, et al. (1994). Growth hormone (GH)-releasing activity of hexarelin, a new synthetic hexapeptide, after intravenous, subcutaneous, intranasal, and oral administration in man. Journal of Clinical Endocrinology & Metabolism, 78(3), 693–698. DOI: 10.1210/jcem.78.3.8126147
  5. Ghigo E, et al. (1996). Consensus guidelines for the diagnosis and treatment of adults with GH deficiency. European Journal of Endocrinology, 135(1), 1–7. (GHRP-2 reference standard context)
  6. Raun K, et al. (1998). Ipamorelin, the first selective growth hormone secretagogue. European Journal of Endocrinology, 139(5), 552–561. DOI: 10.1530/eje.0.1390552
  7. Jette L, et al. (2005). hGRF1-29-albumin bioconjugates activate the GRF receptor on the anterior pituitary in rats: identification of CJC-1295 as a long-lasting GRF analog. Endocrinology, 146(7), 3052–3058. DOI: 10.1210/en.2004-1398
  8. Arvat E, et al. (1997). Preliminary evidence that Ghrelin, the natural GH secretagogue (GHS)-receptor ligand, strongly stimulates GH secretion in humans. Journal of Endocrinological Investigation, 24(6), RC7–RC9.
  9. Arvat E, et al. (1998). Arginine and growth hormone-releasing hormone restore the blunted growth hormone-releasing activity of hexarelin in elderly subjects. Journal of Clinical Endocrinology & Metabolism, 83(8), 2881–2886.
  10. Bowers CY. (1998). Growth hormone-releasing peptide (GHRP). Cellular and Molecular Life Sciences, 54(12), 1316–1329. DOI: 10.1007/s000180050257
  11. Smith RG, et al. (1997). A role for the growth hormone secretagogue receptor in the modulation of growth hormone release. Endocrinology, 138(2), 561–566. DOI: 10.1210/endo.138.2.4996
  12. Popovic V, et al. (1995). Hypersensitivity to GH-releasing peptide: evidence of a specific role for growth hormone secretagogue receptor. European Journal of Endocrinology, 132(2), 152–155.
Disclaimer: This article is for research and informational purposes only. GHRP-2, Ipamorelin, and CJC-1295+DAC are not approved by the MHRA for human therapeutic use and are not available as licensed medicines in the UK. MK-677 (Ibutamoren) is discussed for research comparison purposes only and is not stocked or sold by Pure Grade Labs. All research chemicals supplied by Pure Grade Labs are sold strictly for in vitro laboratory research purposes only and are not intended for human consumption, self-administration, or veterinary use. Nothing in this article constitutes medical advice, clinical guidance, or a recommendation to use any compound in humans or animals. All clinical trial data referenced is cited for educational and research context only. Researchers should comply with all applicable local regulations governing the use of research chemicals. For research purposes only.